Supplementary Table S4 from The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial

Iseult M. Browne; Javier Pascual; Rosalind J. Cutts; Belinda Kingston; Sarah Hrebien; Lucy Suzanne Kilburn; Alex Pearson; Laura J. Moretti; Andrew M. Wardley; Iain R. Macpherson; Richard D. Baird; Rebecca Roylance; Miguel Gil‐Gil; Ángel L. Guerrero-Zotano; Isaac García-Murillas; Judith M. Bliss; Alistair E. Ring; Miguel Martín; Nicholas C. Turner

doi:10.1158/1078-0432.31006801

Supplementary Table S4 from The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial

2026 Open access

Read full text

Authors: Iseult M. Browne, Javier Pascual, Rosalind J. Cutts, Belinda Kingston, Sarah Hrebien, Lucy Suzanne Kilburn, Alex Pearson, Laura J. Moretti, Andrew M. Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance

+7 more

Miguel Gil‐Gil, Ángel L. Guerrero-Zotano, Isaac García-Murillas, Judith M. Bliss, Alistair E. Ring, Miguel Martín, Nicholas C. Turner

DOI: 10.1158/1078-0432.31006801

Cited by: 0

Abstract

C1D1 variants for BRCA1/2 wildtype patients with undetectable ctDNA at C2D1 (CDR = 0) (N=6)

Fields of Study & Subjects

BRCA gene mutations in cancer Cancer Genomics and Diagnostics PARP inhibition in cancer therapy

Publication details

Publication date: 6 January 2026